TENAX THERAPEUTICS, INC. — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Tenax Therapeutics reported Q2 2026 cash and equivalents of $118.0 million (up from $97.6 million at year-end 2025), with $13.4 million raised from warrant exercises in Q2. The company expects topline data from its Phase 3 LEVEL trial for oral levosimendan (TNX-103) in PH-HFpEF in August 2026 and plans presentation at ESC Congress 2026 (Aug 28-31). Q2 R&D expenses doubled to $12.9 million versus $6.1 million prior year due to LEVEL and LEVEL-2 trial costs; net loss widened to $17.8 million versus $10.9 million in Q2 2025.
Why this rating
Phase 3 topline data imminent for lead asset in rare disease; cash sufficient through Q2 2028. Binary catalyst near-term. Material for $23.8M market-cap biotech.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.